SG11201706727XA - Methods, compositions, and kits for treatment of cancer - Google Patents

Methods, compositions, and kits for treatment of cancer

Info

Publication number
SG11201706727XA
SG11201706727XA SG11201706727XA SG11201706727XA SG11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA SG 11201706727X A SG11201706727X A SG 11201706727XA
Authority
SG
Singapore
Prior art keywords
kits
cancer
compositions
treatment
methods
Prior art date
Application number
SG11201706727XA
Other languages
English (en)
Inventor
Jocelyn Holash
Stephen Lau
Original Assignee
Bioclin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioclin Therapeutics Inc filed Critical Bioclin Therapeutics Inc
Publication of SG11201706727XA publication Critical patent/SG11201706727XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11201706727XA 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer SG11201706727XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118350P 2015-02-19 2015-02-19
US201562150235P 2015-04-20 2015-04-20
PCT/US2016/018634 WO2016134234A1 (fr) 2015-02-19 2016-02-19 Méthodes, compositions et trousses pour le traitement du cancer

Publications (1)

Publication Number Publication Date
SG11201706727XA true SG11201706727XA (en) 2017-09-28

Family

ID=56689191

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706727XA SG11201706727XA (en) 2015-02-19 2016-02-19 Methods, compositions, and kits for treatment of cancer

Country Status (12)

Country Link
US (1) US20160243228A1 (fr)
EP (1) EP3258966A4 (fr)
JP (2) JP6774421B2 (fr)
KR (1) KR20170137717A (fr)
CN (1) CN107635583A (fr)
AU (2) AU2016219917B2 (fr)
BR (1) BR112017017700A2 (fr)
CA (1) CA2976638A1 (fr)
IL (1) IL253979B (fr)
MX (1) MX2017010595A (fr)
SG (1) SG11201706727XA (fr)
WO (1) WO2016134234A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932874T3 (es) 2009-03-25 2023-01-27 Genentech Inc Anticuerpos anti-FGFR3 y métodos que utilizan los mismos
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
EP3576792A4 (fr) * 2017-02-06 2020-09-09 Fusion Pharmaceuticals Inc. Méthodes, compositions et trousses pour le traitement du cancer
CN108440673B (zh) * 2018-04-08 2021-08-17 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
US20200277387A1 (en) * 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer
CA3131880A1 (fr) * 2019-03-01 2020-09-10 Fusion Pharmaceuticals Inc. Methodes et compositions pour le traitement du cancer
EP4034118A1 (fr) * 2019-09-26 2022-08-03 Janssen Pharmaceutica NV Utilisation d'inhibiteurs de fgfr dans des cancers génétiquement modifiés par fgfr pour améliorer la réponse du patient à des inhibiteurs du point de contrôle immunitaire dans des conditions de traitement séquentiel
AR123306A1 (es) 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso
US20230330081A1 (en) * 2020-10-28 2023-10-19 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
ES2932874T3 (es) * 2009-03-25 2023-01-27 Genentech Inc Anticuerpos anti-FGFR3 y métodos que utilizan los mismos
US8754114B2 (en) * 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014018841A1 (fr) * 2012-07-27 2014-01-30 Genentech, Inc. Méthodes de traitement d'états associés à fgfr3
PL3021869T3 (pl) * 2013-07-16 2020-11-16 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT

Also Published As

Publication number Publication date
KR20170137717A (ko) 2017-12-13
EP3258966A1 (fr) 2017-12-27
IL253979A0 (en) 2017-10-31
AU2016219917B2 (en) 2021-12-16
JP6774421B2 (ja) 2020-10-21
JP2018507220A (ja) 2018-03-15
IL253979B (en) 2021-06-30
JP7122357B2 (ja) 2022-08-19
MX2017010595A (es) 2018-11-12
AU2022200196A1 (en) 2022-02-10
US20160243228A1 (en) 2016-08-25
CA2976638A1 (fr) 2016-08-25
AU2016219917A1 (en) 2017-09-07
JP2021020909A (ja) 2021-02-18
CN107635583A (zh) 2018-01-26
BR112017017700A2 (pt) 2018-07-31
WO2016134234A1 (fr) 2016-08-25
EP3258966A4 (fr) 2018-07-25

Similar Documents

Publication Publication Date Title
IL258955A (en) Preparations and methods for the treatment of cancer
IL253979B (en) Methods, preparations and kits for cancer treatment
IL267247B (en) Compositions and methods for treating cancer
HK1251408A1 (zh) 治療癌症的方法
IL304820A (en) Preparations and methods for the treatment of cancer
EP3393475A4 (fr) Méthodes de traitement du cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3166640A4 (fr) Compositions de thérapie combinatoire et méthodes de traitement de cancers
HK1247931A1 (zh) 用於診斷和治療癌症的組合物和方法
EP3200815A4 (fr) Procédés et compositions pour le traitement du cancer
IL256523A (en) Compositions and methods for treating cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3325006A4 (fr) Procédés de traitement du cancer exprimant cd166
IL268163A (en) Methods, compositions, and kits for treatment of cancer
EP3328372A4 (fr) Compositions et méthodes de traitement du cancer
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
EP3154544A4 (fr) Compositions et procédés de traitement de cancers
IL255638A (en) Compositions and methods for treating cancer
EP3185910A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3154952A4 (fr) Méthodes et compositions pour traiter les cancers her positifs
EP3268028A4 (fr) Compositions et méthodes pour le traitement d'un cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
EP3160591A4 (fr) Compositions et méthodes pour le traitement du cancer